News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced…

CENTOGENE has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum…

The Company’s Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Japan. CENTOGENE invites…

Adding significant financial expertise with an impressive track record in value creation

The Company’s Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites…

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the…

Company management and the business development team will be attending events in the U.K. and Germany. CENTOGENE invites partners to schedule…

Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community

Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced…

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads

News

CENTOGENE Reports Second Quarter and First Half 2022 Financial Results

CENTOGENE Receives Nasdaq Non-Compliance Notice

CENTOGENE to Participate in Upcoming Conferences in December

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

CENTOGENE to Participate in Upcoming Conferences in November

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

CENTOGENE to Participate in Upcoming Partnering Conferences in October

CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics

CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September

CENTOGENE Reports First Quarter 2022 Financial Results On Track for FY 2022 Guidance

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Downloads